Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Patients With Malignant Blood Disease Requiring Hepatitis B Antiviral Medication 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, B-Cell 1Hepatitis B Reactivation 1Hepatitis B 1

Interventions

entecavir 10Lamivudine 5Tenofovir 4lenvatinib 2Sorafenib 2Radiofrequency Ablation 2Hepatitis B Vaccines 2tenofovir alafenamide 1polysaccharide MGN3 1peginterferon alfa-2b 1peginterferon alfa-2a 1navitoclax 1menatetrenone 1lens intermediate filament proteins 1human papillomavirus vaccine, L1 type 16, 18 1hepatitis B hyperimmune globulin 1bicyclol 1adefovir dipivoxil 1adefovir 1Urinalysis 1Ultrasonography 1Tumor Necrosis Factor-alpha 1Tetanus Toxoid 1Telbivudine 1Tablets 1Standard of Care 1Rapid Diagnostic Tests 1Raltegravir Potassium 1Radiomics 1Practice Guidelines as Topic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hepatitis B × tenofovir alafenamide × Clear all
NCT03887702 2024-05-20

Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors

SWOG Cancer Research Network

Phase 3 Terminated
4 enrolled 5 charts

Hepatitis B

Data powered by HemOnc (CC BY 4.0) Colophon âš¡